Soleno Therapeutics
SLNO
SLNO was delisted on the 15th of May, 2026.
33 hedge funds and large institutions have $48.5M invested in Soleno Therapeutics in 2020 Q1 according to their latest regulatory filings, with 13 funds opening new positions, 8 increasing their positions, 5 reducing their positions, and 1 closing their positions.
1,200% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 1
60% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 5
57% more funds holding
Funds holding: 21 → 33 (+12)
0.45% more ownership
Funds ownership: 2.65% → 3.1% (+0.45%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
6% less capital invested
Capital invested by funds: $51.6M → $48.5M (-$3.03M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VC
Vivo Capital
Palo Alto,
California
|
+$5.73M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.2M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
+$1.09M |
| 4 |
BNP Paribas Financial Markets
Paris,
France
|
+$397K |
| 5 |
Millennium Management
New York
|
+$384K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Birchview Capital
Burlington,
Vermont
|
-$877K |
| 2 |
JGC
J. Goldman & Co
New York
|
-$191K |
| 3 |
SAM
Shikiar Asset Management
New York
|
-$104K |
| 4 |
6CM
683 Capital Management
New York
|
-$62.1K |
| 5 |
Renaissance Technologies
New York
|
-$40.5K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
LC
26
Lindbrook Capital
Calabasas,
California
| $22K | -$4.51K | -106 | -14% |
|
27
Bank of America
Charlotte,
North Carolina
| $19K | +$23.1K | +543 | +27,150% |
|
28
UBS Group
Zurich,
Switzerland
| $13K | +$9.91K | +233 | +196% |
|
|
MF
29
Manchester Financial
Westlake Village,
California
| $5K | +$5.66K | +133 | New |
|
|
CSS
30
Cubist Systematic Strategies
Stamford,
Connecticut
| $2K | +$1.79K | +42 | New |
|
31
Royal Bank of Canada
Toronto,
Ontario, Canada
| $1K | – | – | – |
|
32
Morgan Stanley
New York
| $1K | +$936 | +22 | +440% |
|
|
SAM
33
Shikiar Asset Management
New York
| – | -$104K | -2,367 | Closed |
|
34
Wells Fargo
San Francisco,
California
| – | +$383 | +9 | New |
|
SLNO Hedge Fund Activity: Q1 2020 in Review
33 of the 4,539 institutional investors tracked by Wall St. Rank reported a position in Soleno Therapeutics (SLNO) for Q1 2020, worth a combined $48.5M — down 5.9% from $51.6M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new SLNO positions and 1 closed out — a net gain of 12 holders — while 8 added to existing stakes and 5 trimmed.
The largest buyer was Vivo Capital, opening a new position worth an estimated $5.73M. The largest seller was Birchview Capital, cutting an estimated $877K.
- 33 institutional investors held Soleno Therapeutics (SLNO) as of Q1 2020, up from 21 in Q4 2019.
- Funds reported $48.5M of Soleno Therapeutics stock for Q1 2020, down 5.9% quarter-over-quarter.
- 13 funds opened new Soleno Therapeutics positions in Q1 2020 and 1 closed out, a net change of +12 holders.
- The largest Soleno Therapeutics buyer in Q1 2020 was Vivo Capital, an estimated $5.73M added.
- The largest Soleno Therapeutics seller in Q1 2020 was Birchview Capital, an estimated $877K sold.
Based on aggregated 13F filings for Q1 2020.